Raymond James analyst Steven Seedhouse downgraded Jounce Therapeutics to Outperform from Strong Buy with a price target of $3, down from $16.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on JNCE:
- Jounce Therapeutics expects cash to fund operating expenses into 1Q24
- Jounce Therapeutics reports Q3 EPS (60c), consensus (64c)
- Jounce Therapeutics Reports Third Quarter 2022 Financial Results
- Jounce Therapeutics to Announce Third Quarter 2022 Financial Results and Host Conference Call on Thursday, November 10, 2022
- Jounce Therapeutics to Present Multiple Posters at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting and the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) Annual Congress
Questions or Comments about the article? Write to editor@tipranks.com